Evidence map›Paper›PMID 31243334›Full record

ReviewNature reviews. Clinical oncology2019

Assessing the interactions between radiotherapy and antitumour immunity.

Clemens Grassberger, Susannah G Ellsworth, Moses Q Wilks, Florence K Keane, Jay S Loeffler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 3 pooled it
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 3 syntheses or guidelines pooled it, 245 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Clemens GrassbergerDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Grassberger.Clemens@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-4425-4489
Susannah G EllsworthDepartment of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
Moses Q WilksGordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.
Florence K KeaneDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Jay S LoefflerDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Harvard University · USGordon Center for Medical Imaging · USIndiana University School of Medicine

Funding

Statistics, Data Exchange, Management and SupportP01CA021239 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DELANEY, THOMAS F · 1985 to 2013
$28.3M
Bio-Physical Modeling of Immuno-Radiotherapy Combinations based on Patient DataR21CA241918 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GRASSBERGER, CLEMENS · 2019 to 2020
$399k
NCI NIH HHS P01 CA021239NCI NIH HHS R21 CA241918
6 · The paper itself

Abstract

Immunotherapy, specifically the introduction of immune checkpoint inhibitors, has transformed the treatment of cancer, enabling long-term tumour control even in individuals with advanced-stage disease. Unfortunately, only a small subset of patients show a response to currently available immunotherapies. Despite a growing consensus that combining immune checkpoint inhibitors with radiotherapy can increase response rates, this approach might be limited by the development of persistent radiation-induced immunosuppression. The ultimate goal of combining immunotherapy with radiotherapy is to induce a shift from an ineffective, pre-existing immune response to a long-lasting, therapy-induced immune response at all sites of disease. To achieve this goal and enable the adaptation and monitoring of individualized treatment approaches, assessment of the dynamic changes in the immune system at the patient level is essential. In this Review, we summarize the available clinical data, including forthcoming methods to assess the immune response to radiotherapy at the patient level, ranging from serum biomarkers to imaging techniques that enable investigation of immune cell dynamics in patients. Furthermore, we discuss modelling approaches that have been developed to predict the interaction of immunotherapy with radiotherapy, and highlight how they could be combined with biomarkers of antitumour immunity to optimize radiotherapy regimens and maximize their synergy with immunotherapy.

Indexed as

ImmunotherapyRadiotherapyCombined Modality TherapyHumansImmune SystemNeoplasmsPrecision Medicine

Identifiers

PMID31243334
PMCPMC13492067
OpenAlexW2954542121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.